Results 51 to 60 of about 121,700,018 (217)

The light chain but not the heavy chain of botulinum A toxin inhibits exocytosis from permeabilized adrenal chromaffin cells [PDF]

, 1989
The heavy and light chains of botulinum A toxin were separated by anion exchange chromatography. Their intracellular actions were studied using bovine adrenal chromaffin cells permeabilized with streptolysin O.
M. Gratzl, Weller, U., Ahnert-Hilger, G., B. Stecher, G. Ahnert-Hilger, Gratzl, Manfred, Habermann, E., Stecher, B., E. Habermann, U. Weller   +9 more
core   +1 more source

Analysis of a unique Clostridium botulinum strain from the Southern hemisphere producing a novel type E botulinum neurotoxin subtype

BMC Microbiology, 2012
Background Clostridium botulinum strains that produce botulinum neurotoxin type E (BoNT/E) are most commonly isolated from botulism cases, marine environments, and animals in regions of high latitude in the Northern hemisphere. A strain of C.
Raphael Brian H, Lautenschlager Matthew, Kalb Suzanne R, de Jong Laura I T, Frace Michael, Lúquez Carolina, Barr John R, Fernández Rafael A, Maslanka Susan E   +8 more
doaj   +1 more source

Foodborne Botulism, Canada, 2006–2021

Emerging Infectious Diseases, 2023
During 2006–2021, Canada had 55 laboratory-confirmed outbreaks of foodborne botulism, involving 67 cases. The mean annual incidence was 0.01 case/100,000 population.
Richard A. Harris, Christine Tchao, Natalie Prystajecky, Kelly Weedmark, Yassen Tcholakov, Manon Lefebvre, John W. Austin   +6 more
doaj   +1 more source

Neuropathic pain in cerebral palsy and related genetic conditions: A scoping review of prevalence, characteristics, and management

Developmental Medicine &Child Neurology, EarlyView.
Abstract Aim To map existing evidence on neuropathic pain in cerebral palsy (CP) and related genetic conditions, including prevalence, descriptors, assessment methods, and management. Method Following prospective registration, five databases (Ovid MEDLINE, Embase, CINAHL, Web of Science, Google Scholar) were searched in June 2025.
Aayushi Khillan, Sanya Verma, Hannah Yeomans, Karen Bau, Caitlin Doyle, Monica S. Cooper, David J. Amor, Carolyn Berryman, Adrienne Harvey   +8 more
wiley   +1 more source

Protein Domain Analysis of C. botulinum Type A Neurotoxin and Its Relationship with Other Botulinum Serotypes

, 2009
Botulinum neurotoxins (BoNTs) are highly potent poisons produced by seven serotypes of Clostridium botulinum. The mechanism of neurotoxin action is a multistep process which leads to the cleavage of one of three different SNARE proteins essential for ...
Shashi K. Sharma, Uma Basavanna, Hem D. Shukla   +2 more
core   +1 more source

Passive shoulder mobility and active shoulder external rotation recovery in upper‐trunk brachial plexus birth injuries after nerve repair

Developmental Medicine &Child Neurology, Volume 68, Issue 12, Page 1712-1719, December 2026.
This was a retrospective cohort study of 322 patients with upper trunk brachial plexus birth injury following nerve surgery of C5 and/or C6. We found that a substantial gap remained between passive and active shoulder external rotation in adduction, indicating that passive mobility is not the limiting factor in active external rotation recovery ...
Eva T. E. Ulmann, Jochem Nagels, Willem Pondaag, Martijn J. A. Malessy   +3 more
wiley   +1 more source

Producing positive control materials for template in PCR testing to detect botulinum neurotoxin types A and B genes

Tạp chí Kiểm nghiệm và An toàn thực phẩm
Botulinum neurotoxin (BoNT) is produced by the bacterium Clostridium botulinum and some other bacterial strains such as C. butyricum and C. baratii. It is considered the strongest toxin known to humans and can cause botulism.
Ninh Thi Hanh, Le Vinh Hoa, Tran Hong Ba, Pham Van Quan, Le Thanh Long, Pham Thi Loan   +5 more
doaj   +1 more source

How Can We Personalize the Delivery of Onabotulinumtoxin‐A for Patients With Neurogenic Lower Urinary Tract Dysfunction?

Neurourology and Urodynamics, Volume 45, Issue 8, Page 1500-1506, November 2026.
ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang, William I. Jaffe, Ariana L. Smith   +2 more
wiley   +1 more source

A closer look to botulinum neurotoxin type A-induced analgesia

Toxicon, 2013
Chronic pain indicates a type of pain that lasts over time and is accompanied by diagnostic and therapeutic difficulties. It follows that treatment failures are common and patients roam from doctor to doctor in search of an effective care program. So there is an urgent need for long-acting and effective therapeutics to alleviate symptoms of the varied ...
Guo, Bao-Lin, Zheng, Chen-Xi, Sui, Bing-Dong, Li, Yun-Qing, Wang, Ya-Yun, Yang, Yan-Ling   +5 more
openaire   +2 more sources

Structural Basis for BABIM Inhibition of Botulinum Neurotoxin Type B Protease

, 2016
Structural Basis for BABIM Inhibition of Botulinum Neurotoxin Type B ...
Michael A. Hanson (2213152), Daniel H. Rich (1972099), Raymond C. Stevens (270962), Chanokporn Sukonpan (2984046), Thorsten K. Oost (2503873)   +4 more
core   +1 more source